Abstract |
We analysed participants with type 2 diabetes (n = 46) within a larger weight loss trial (n = 146) who were randomized to 48 weeks of a low-carbohydrate diet (LCD; n = 22) or a low-fat diet + orlistat (LFD + O; n = 24). At baseline, mean body mass index (BMI) was 39.5 kg/m(2) (s.d. 6.5) and haemoglobin A1c (HbA1c) 7.6% (s.d. 1.3). Although the interventions reduced BMI similarly (LCD -2.4 kg/m(2) ; LFD + O -2.7 kg/m(2) , p = 0.7), LCD led to a relative improvement in HbA1c: -0.7% in LCD versus +0.2% in LFD + O [difference -0.8%, 95% confidence interval (CI) = -1.6, -0.02; p = 0.045]. LCD also led to a greater reduction in antiglycaemic medications using a novel medication effect score (MES) based on medication potency and total daily dose; 70.6% of LCD versus 30.4% LFD + O decreased their MES by ≥50% (p = 0.01). Lowering dietary carbohydrate intake demonstrated benefits on glycaemic control beyond its weight loss effects, while at the same time lowering antiglycaemic medication requirements.
|
Authors | S B Mayer, A S Jeffreys, M K Olsen, J R McDuffie, M N Feinglos, W S Yancy Jr |
Journal | Diabetes, obesity & metabolism
(Diabetes Obes Metab)
Vol. 16
Issue 1
Pg. 90-3
(Jan 2014)
ISSN: 1463-1326 [Electronic] England |
PMID | 23911112
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.)
|
Copyright | © 2013 John Wiley & Sons Ltd. |
Chemical References |
- Blood Glucose
- Glycated Hemoglobin A
- Hypoglycemic Agents
- hemoglobin A1c protein, human
|
Topics |
- Blood Glucose
(metabolism)
- Body Mass Index
- Diabetes Mellitus, Type 2
(diet therapy, drug therapy, metabolism)
- Diet, Carbohydrate-Restricted
- Diet, Fat-Restricted
- Diet, Reducing
- Female
- Glycated Hemoglobin
(metabolism)
- Humans
- Hypoglycemic Agents
(pharmacology)
- Male
- Middle Aged
- Patient Compliance
- Treatment Outcome
- Weight Loss
|